- In the phase of trials, the company will be enrolling over 1,000 subjects across multiple clinical study sites in India, it said in a regulatory filing.
- The adaptive phase I/ II
human clinical trials of ZyCoV-D have commenced with the first human dosing, it said, adding that "the adaptive phase I/II dose escalation, multi-centric study will assess the safety, tolerability and immunogenicity of the vaccine." - Earlier this month, Zydus had received approval from domestic authorities to start human trials for its COVID-19 vaccine contender - the second Indian pharmaceutical firm to get such nod amid a surge in novel
coronavirus infections worldwide.
The adaptive phase I/ II human clinical trials of ZyCoV-D have commenced with the first human dosing, it said, adding that "the adaptive phase I/II dose escalation, multi-centric study will assess the safety, tolerability and immunogenicity of the vaccine."
Earlier this month, Zydus had received approval from domestic authorities to start human trials for its COVID-19 vaccine contender - the second Indian pharmaceutical firm to get such nod amid a surge in novel coronavirus infections worldwide.
It got approval a few days after India's first indigenous COVID-19 vaccine candidate COVAXIN, developed by city-based
Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 356.50 apiece on BSE, up 0.81 per cent against their previous close.
SEE ALSO:
INTERVIEW: Shaaz Jung opens up about the blood, sweat and years behind the viral images of a rare black panther
Intel will speed up Mukesh Ambani’s 5G run, power him with AI and possibly a Jio laptop— all in return for massive amount of data